Clinical Trials · NCT00543023
A Study of the Treatment of Postmenopausal Women With Osteoporosis
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 104
- Start date
- Jun 2003
- Locations
- 2 sites, China
- Primary endpoint
- to compare the effect of treatment with teriparatide 20 micrograms/day subcutaneous with that of salmon calcitonin 100 IU/day subcutaneous on change in lumbar spine BMD in postmenopausal women with established osteoporosis.